One dose of vaccine against Japanese encephalitis provides sustained protection

October 13, 2005

A single-dose of a live vaccine against Japanese encephalitis can give children in Nepal high levels of protection for over a year, according to an article in this week's issue of The Lancet.

Japanese encephalitis is an infection transmitted through the rice-growing areas of Asia by several types of vector mosquito. It causes at least 50,000 clinical cases and 10,000 deaths every year in Asia. While some Asian countries have nearly eliminated Japanese encephalitis or reduced its incidence, in other countries, such as Nepal and India, the disease has become a substantial public-health problem.

In a previous study in July 1999, Heechoul Ohrr (Yonsei University College, Korea) and colleagues, found that a single dose of live-attenuated SA 14-14-2 Japanese encephalitis vaccine was 99.3% effective in Nepalese children aged 1-15 years. In the latest study the team assessed the long-term effect of this vaccine. No additional vaccine was given to the population. An outbreak of the disease was seen in Nepal during August and September 2000. The researchers assessed the situation after this outbreak and found that a single dose of the vaccine had a protective effect of 98.5%12-15 months after immunisation.

Professor Ohrr concludes "Because of the large vaccine-eligible population in the Asian-Pacific region and the short supply of Japanese encephalitis vaccine, the high protective effect of one dose of SA 14-14-2 vaccine lends support to the integration of a single dose, where licensed for use, into the WHO Expanded Programme on Immunisation (EPI) schedule at 12-15 months."
-end-
See also accompanying comment.

Contact: Dr Heechoul Ohrr, Department of Preventive Medicine, Yonsei University College of Medicine, Seoul 120-752, Republic of Korea. ohrr@yumc.yonsei.ac.kr

Lancet

Related Vaccine Articles from Brightsurf:

Who should get the COVID-19 vaccine first?
Nineteen global health experts from around the world have proposed a new, three-phase plan for vaccine distribution -- called the Fair Priority Model -- which aims to reduce premature deaths and other irreversible health consequences from COVID-19.

Breakthrough with cancer vaccine
Scientists have developed a new cancer vaccine with the potential to activate the body's immune system to fight a range of cancers, including leukaemia, breast cancer, lung cancer and pancreatic cancers.

How to improve the pneumococcus vaccine
Pneumococcus kills 1 million children annually according to the World Health Organization.

US inroads to better Ebola vaccine
As the world focuses on finding a COVID-19 vaccine, research continues on other potentially catastrophic pandemic diseases, including Ebola and Marburg viruses.

Successful MERS vaccine in mice may hold promise for COVID-19 vaccine
In a new study, published April 7 in mBio, researchers from the University of Iowa and the University of Georgia demonstrate that a new vaccine fully protects mice against a lethal dose of MERS, a close cousin of COVID-19.

Coronavirus Vaccine: Where are we and what's next? (video)
You might have heard that COVID-19 vaccine trials are underway in Seattle.

Why isn't there a vaccine for staph?
A study from Washington University School of Medicine in St.

Exposing vaccine hesitant to real-life pain of diseases makes them more pro-vaccine
New research from Brigham Young University professors finds there is a better way to help increase support for vaccinations: Expose people to the pain and suffering caused by vaccine-preventable diseases instead of trying to combat people with vaccine facts.

Lifetime flu vaccine?
Another year, another flu vaccine because so far scientists haven't managed to make a vaccine that protects against all strains of flu.

On the horizon: An acne vaccine
A new study published in the Journal of Investigative Dermatology reports important steps that have been taken towards the development of an acne vaccine.

Read More: Vaccine News and Vaccine Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.